NDAC’s Wood Departs FDA Committee; Joins Private Investment Firm
This article was originally published in The Tan Sheet
Executive Summary
Nonprescription Drugs Advisory Committee Chairman Alastair Wood, MD, will depart NDAC in May and take a position at New York-based private equity firm Symphony Capital, the company announced May 1